A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis

Journal of Applied Oral Science

Volumn 19, Issue 4, 2011, Pages 293-300

  Sacco, Roberto ^a   Sacco, Gianluca ^a   Acocella, Alessandro ^b   Sale, Silvana ^a   Sacco, Nicola ^c   Baldoni, Edoardo ^a  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c NONE

Author keywords

Bisphosphonates; Jaw diseases; Osteonecrosis

Indexed keywords

EID: 80053182824     PISSN: 16787757     EISSN: 16787765     Source Type: Journal    
DOI: 10.1590/S1678-77572011000400001     Document Type: Review

References (47)

1. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.
2. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg. 2007;18:1071-5.
3. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg. 2008;66:987-94.
4. Allen MR, Follet H, Khurana M, Sato M, Burr DB. Antiremodeling agents influence osteoblast activity differently in modeling and remodelling sites of canine rib. Calcif Tissue Int. 2006;79:255-61.
5. Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006;39:872-9.
6. Anthony JP, Foster RD. Mandibular reconstruction with the fibula osteocutaneous free flap. Oper Tech Plast Rec Surg. 1996;3(4):233-40.
7. Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metab. 2010;54:206-12.
8. Assael LA. New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;62:125-6.
9. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res. 1995;10:211-21.
10. Buchbinder D, St. Hilaire H. The use of free tissue transfer in advanced osteoradionecrosis of the mandible. J Oral Maxillofac Surg. 2006;64:961-4.
11. Duncan MJ, Manktelow RT, Zuker RM, Rosen IB. Mandibular reconstruction in the radiated patient: the role of osteocutaneous free tissue transfers. Plast Reconstr Surg. 1985;76:829-40.
12. Engroff LS, Kim DD. Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction? J Oral Maxillofac Surg. 2007;65:2374-85.
13. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002;31:620-5.
14. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006;116:115-20.
15. Ferrari S, Bianchi B, Savi A, Poli T, Multinu A, Balestreri A. Fibula free flap with endosseous implants for reconstructing a resected mandible in bisphosphonate osteonecrosis. J Oral Maxillofac Surg. 2008;66:999-1003.
16. Gliklich R, Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry. J Oral Maxillofac Surg. 2009;67(Sp. Iss. 5):71-4.
17. Goodacre TE, Walker CJ, Jawad AS, Jackson AM, Brough MD. Donor site morbidity following osteocutaneous free fibula transfer. Br J Plast Surg. 1990;43:410-2.
18. Greenberg MS. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98:259-60.
19. Griz L, Caldas G, Bandeira C, Assunção V, Bandeira F. Paget's disease of bone. Arq Bras Endocrinol Metabol. 2006;50:814-22.
20. Hsu CC, Chuang YW, Lin CY, Huang YF. Solitary fibular metastasis from lung cancer mimicking stress fracture. Clin Nucl Med. 2006;31:269-71.
21. Iwata K, Li J, Follet H, Phipps RJ, Burr DB. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone. 2006;39:1053-8.
22. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-91.
23. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.
24. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
25. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-75.
26. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613-20.
27. McDonald MM, Dulai S, Godfrey C, Amanat N, Sztynda T, Little DG. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. Bone. 2008;43:653-62.
28. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4.
29. Mücke T, Haarmann S, Wolff KD, Hölzle F. Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Craniomaxillofacial Surg. 2009;37:291-7.
30. Nocini PF, Saia G, Bettini G, Ragazzo M, Blandamura S, Chiarini L, et al. Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis. Eur J Surg Oncol. 2009;35:373-9.
31. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signalregulated kinase activation. J Biol Chem. 2005;280:7317-25.
32. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-74.
33. Reiriz AB, De Zorzi PM, Lovat CP. Bisphosphonates and osteonecrosis of the jaw: a case report. Clinics (Sao Paulo). 2008;63:281-4.
34. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-6.
35. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100-3.
36. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemical markers of bone turnover in the follow up of patients treated with bisphosphonates. Calcif Tissue Int. 1998;63:363-8.
37. Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated with the use of bisphosphonates. J Oral Maxillofac Surg. 2003;61(Sp. Iss.):60.
38. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE. Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. J Oral Maxillofac Surg. 2009;35:119-30.
39. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34.
40. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-59.
41. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57.
42. Santamaria Júnior M, Fracalossi AC, Consolaro MF, Consolaro A. Influence of bisphosphonates on alveolar bone density: a histomorphometric analysis. Braz Oral Res. 2010;24:309-15.
43. Sarathy AP, Bourgeois SL Jr, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod. 2005;31:759-63.
44. Seth R, Futran ND, Alam DS, Knott PD. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope. 2010;120:2165-71.
45. Urken ML. Composite free flaps in oromandibular reconstruction. Review of the literature. Arch Otolaryngol Head Neck Surg. 1991;117:724-32.
46. Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd:YAG laser biostimulation of bisphosphonate-associated necrosis of the jawbone with and without surgical treatment. Br J Oral Maxillofac Surg. 2007;45:628-32.
47. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104-7.